Siren, L.L.C. Arcus Biosciences, Inc. Transaction History
Siren, L.L.C.
- $1.93 Trillion
- Q2 2025
A detailed history of Siren, L.L.C. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Siren, L.L.C. holds 1,612,077 shares of RCUS stock, worth $15.6 Million. This represents 0.68% of its overall portfolio holdings.
Number of Shares
1,612,077
Previous 1,612,077
-0.0%
Holding current value
$15.6 Million
Previous $12.7 Billion
3.69%
% of portfolio
0.68%
Previous 0.71%
Shares
1 transactions
Others Institutions Holding RCUS
# of Institutions
207Shares Held
67MCall Options Held
3.18MPut Options Held
167K-
Black Rock Inc. New York, NY9.76MShares$94.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.56MShares$63.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$57.7 Million0.11% of portfolio
-
Woodline Partners LP San Francisco, CA4MShares$38.7 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$35.7 Million1.03% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $698M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...